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Spinal and bulbar muscular atrophy (SBMA) is a
neurodegenerative disease caused by a polyglut-
amine expansion in the androgen receptor (AR) and
is associated with misfolding and aggregation of the
mutant AR. We investigated the role of an interdo-
main interaction between the amino (N)-terminal
FxxLF motif and carboxyl (C)-terminal AF-2 domain
in a mouse model of SBMA. Male transgenic mice
expressing polyQ-expanded AR with a mutation in
the FxxLF motif (F23A) to prevent the N/C interac-
tion displayed substantially improved motor func-
tion compared with N/C-intact AR-expressing mice
and showed reduced pathological features of
SBMA. Serine 16 phosphorylation was substantially
enhanced by the F23A mutation; moreover, the pro-
tective effect of AR F23A was dependent on this
phosphorylation. These results reveal an important
role for the N/C interaction on disease onset in mice
and suggest that targeting AR conformation could
be a therapeutic strategy for patients with SBMA.
INTRODUCTION
The polyglutamine (polyQ) expansion diseases comprise a family
of adult-onset neurodegenerative diseasescausedby theexpan-
sion of a CAG trinucleotide repeat within the coding region of the
affected gene. Spinal and bulbar muscular atrophy (SBMA) is a
neuromuscular disease that is a member of this family and is
caused by the expansion of a polymorphic CAG tract in the
androgen receptor (AR) gene (La Spada et al., 1991). Men with
an expansion of the repeat beyond 39 CAGs exhibit proximal
muscleweakness andatrophy,muscle fasciculations, dysphagia
anddysarthria, and largely subclinical sensory deficits, beginning2312 Cell Reports 13, 2312–2323, December 15, 2015 ª2015 The Auin the third to fifth decade of life (Harding et al., 1982; Li et al.,
1995; Sobue et al., 1989;Wilde et al., 1987). Histological analysis
reveals a lossof lowermotor neurons from thebrain stemandspi-
nal cord and the nuclear accumulation of polyQ-expanded AR
within inclusions in neuronal (and to a lesser extent non-neuronal)
tissues (Li et al., 1998a, 1998b). Both myopathic features and
neurogenic muscle atrophy are observed in diseased muscle
(Soraru` et al., 2008). Although SBMA patients may show signs
of androgen insensitivity, such as reduced fertility and gyneco-
mastia, the neurological symptoms are not primarily caused by
reducedAR function. This conclusion is basedon theobservation
that chromosomal XY individuals with complete androgen insen-
sitivity do not exhibit neurological symptoms (Brinkmann, 2001).
Thus, polyQ expansion appears to cause SBMA through the
acquisition of a toxicARproperty, although themechanistic basis
of toxicity is still largely unknown.
An appreciation of the role of protein context in the pathogenic
mechanism of polyQ expansion diseases has emerged in recent
years (Duvick et al., 2010; Lamet al., 2006; Nedelsky et al., 2010).
One of the clearest examples of such a role is the requirement for
androgen binding by the polyQ-expanded AR in SBMA (Cheva-
lier-Larsen et al., 2004; Katsuno et al., 2002; Takeyama et al.,
2002; Walcott andMerry, 2002). The AR is a ligand-activated nu-
clear receptor that is regulated by the binding of the androgenic
hormones testosterone or dihydrotestosterone to the carboxyl-
terminal ligand-binding domain. Hormone binding to the AR in-
duces an interdomain interaction between the amino-terminal
(N) 23FQNLF27 motif and the carboxyl-terminal (C) AF2 domain
(Doesburg et al., 1997; He et al., 1999, 2000). This N/C interac-
tion stabilizes hormone binding (He et al., 1999), increases
protein half-life, and is necessary for full transcriptional activity
of the AR (He et al., 2002). In cell models of SBMA, pharmacolog-
ical or genetic inhibition of the N/C interaction decreases the ag-
gregation and toxicity of polyQ-expanded AR (Orr et al., 2010).
However, whether the N/C interaction is required for disease
symptoms and pathological changes in vivo, in a mammalian
model of SBMA, is unknown.thors
Figure 1. The N/C Interaction of AR Is Necessary for Toxicity in
Motor Neurons
(A) Motor neuron cultures were infected with AAV expressing AR F23A 110Q
or AR 112Q for 5 days and then treated with ethanol or DHT for 7 days. The
number of motor neurons was counted following identification by immuno-
staining with an antibody detecting unphosphorylated-NFH (SMI32).
(B) Expression of AR 112Q caused DHT-dependent toxicity (*p < 0.05), while
AR F23A 110Q did not cause toxicity, despite producing higher expression (B).
Error bars represent SD. Infected motor neurons were harvested for protein
5 days after treatment with virus. The infectivity of virus expressing AR F23
110Q (83%) was higher than virus expressing AR 112Q virus (61%).Here we used mouse models to investigate whether the AR
N/C interaction is involved in the development of disease pheno-
types associated with SBMA. By analyzing motor symptoms
and pathology in transgenic mice expressing a polyQ-expanded
AR with or without a mutated 23FQNLF27motif, we found that
preventing the AR N/C interaction substantially delayed motor
deficits and prevented or reduced pathological changes in spinal
motor neurons and muscle. Moreover, mutation of the FxxLF
motif prevented androgen-dependent mutant AR toxicity in
primary cultured motor neurons. Mechanistically, preventing
the N/C interaction by mutation of the FxxLF motif led to
Ser-16 hyperphosphorylation. Furthermore, mutation of Ser-16
completely eliminated the protection afforded by FxxLFmutation
in cell models of SBMA, indicating a requirement for Ser-16 in
mediating F23A neuroprotection. Our results reveal a critical
role for an androgen-dependent AR conformation and post-
translational modification state at Ser-16 in SBMA pathogenesis.
RESULTS
The N/C Interaction of AR Is Necessary for Toxicity in
Motor Neurons
Mutation of the FxxLFmotif at the first phenylalanine (F23A) elim-
inates the N/C interaction of both normal (He et al., 2000) and
polyQ-expanded (Orr et al., 2010) AR. In order to examine theCell Reprole of the interdomain N/C interaction in androgen-dependent,
expanded AR toxicity in spinal motor neurons, we used adeno-
associated virus (AAV) to transduce dissociated embryonic
mouse spinal cord cultures with polyQ-expanded AR with or
without a mutation of the first phenylalanine of the FxxLF
motif. Expression of AR 112Q caused DHT-dependent toxicity
in cultured motor neurons (Figure 1A) as previously described
(Mojsilovic-Petrovic et al., 2009; Montie et al., 2009; Orr et al.,
2010). However, AR 110Q with a mutated FxxLF motif (F23A)
failed to induce DHT-dependent toxicity (Figure 1A), despite
higher AR expression (Figure 1B). No evidence of nuclear inclu-
sions or of aggregated AR species was present at the time of cell
death assessment (data not shown, Heine et al., 2015); thus, it is
unlikely that differences in AR aggregation, leading to reduced
levels of soluble AR F23A, explain this neuroprotection. These
findings reveal that polyQ-expanded AR with a deficient N/C
interaction is unable to induce DHT-dependent toxicity in motor
neurons.
Generating AR F23A Transgenic Mice
In order to understand the role of the AR N/C interaction in vivo,
we generated transgenic mice expressing AR with the F23A mu-
tation and either 108Q or 22Q, driven by the prion protein (PrP)
promoter. This promoter was previously used to drive transgene
expression in a mouse model of SBMA that reproduces the
slowly progressive motor dysfunction and pathological changes
observed in SBMA patients (Chevalier-Larsen et al., 2004; Mon-
tie et al., 2009). Transgene mRNA levels were equivalent or
slightly higher in the brain and spinal cord of AR F23A 108Q-ex-
pressingmice comparedwith the corresponding tissues fromAR
112Q-expressing mice (Figure S1A). Transgenic protein expres-
sion,measured at 7weeks of age to avoid the complication of AR
aggregation, was slightly higher in AR F23A 108Q (Figure S1B)
and substantially higher in AR F23A 22Q mice (Figure S1C)
compared with AR 112Qmice. Given the dependence of disease
phenotypes on protein expression levels, we concluded that the
F23Amice generated here would provide a robust test of the role
of the AR N/C interaction in disease.
In order to analyze the effect of the F23A mutation on SBMA
disease characteristics, we generated male cohorts of AR
112Q, AR F23A 108Q, AR F23A 22Q, and non-transgenic mice.
Additionally, we analyzed female cohorts of AR 112Q and AR
F23A 108Q to evaluate any androgen-independent effects of
AR F23A 108Q.
Blocking the N/C Interaction of the AR Delays Motor
Deficits
In order to evaluate motor function, we analyzed the established
large cohorts of mice on an accelerating rotarod every 4 weeks
beginning at 8 weeks of age. Male AR 112Q mice were worse
than non-transgenic males beginning at 8 weeks of age (Fig-
ure 2A) (p < 0.05) and worse than AR F23A 108Q mice beginning
at 12 weeks of age (p < 0.05) (Figure 2A). In contrast, AR F23A
108Q males were no different than non-transgenic males until
32 weeks of age (Figure 2A).
Male AR F23A 108Qmice failed to gain weight with age, unlike
male non-transgenic andAR112Qmice in this cohort (Figure 2C).
As weight is inversely correlated with rotarod performanceorts 13, 2312–2323, December 15, 2015 ª2015 The Authors 2313
Figure 2. Preventing the N/C Interaction of the polyQ-Expanded AR-Delayed Rotarod Deficits in Male Mice
(A) AR 112Q male mice were significantly worse on the rotarod than AR F23A 108Q and non-transgenic (ntg) mice by 12 weeks of age. However, AR F23A 108Q
male mice were no different from ntgmice until 32 weeks of age. (#, AR 112Q significantly worse than ntg, p < 0.05; *, AR 112Q significantly worse than ntg and AR
F23A 108Q, p < 0.05; **, all lines significantly different from each other, p < 0.05).
(B) No difference in rotarod was seen between females of the three cohorts tested.
(C) AR F23A expression decreased body weights of F23A mice. AR F23A 108Q males (n = 22) weighed less than ntg males (n = 22) and AR 112Q male mice
(n = 20). (*, AR 112Qmice significantly heavier than ntg and AR F23A 108Q, p < 0.05; #, all lines were significantly different from each other, p < 0.05; **, AR F23A
108Q mice weighed significantly less than ntg and AR 112Q males, p < 0.001).
(D) AR F23A 108Q females (n = 20) weighed less than AR 112Q females (n = 16) at 10 and 24 weeks (*p < 0.05). At 16 and 20 weeks, AR F23A 108Q females
weighed less than both ntg (n = 20) and AR 112Q mice (#, p < 0.05).
(E and F) Rotarod performance and body weights from a pilot study with AR F23A 108Qmice. (E) AR 112Qmale mice showed a decline in rotarod performance at
12 weeks of age (*p < 0.05). AR F23A 108Q male mice (n = 11) were no different than non-transgenic male mice (n = 11) until 32 weeks of age (**p < 0.05) (*, AR
112Q significantly worse than both non-transgenic mice and AR F23A 108Q; **, AR112Q and AR F23A 108Q significantly worse than non-transgenic mice). (F) AR
F23A 108Qmale mice weighed significantly less than AR 112Qmice (n = 4) at 12 and 16 weeks of age (*p < 0.05) and less than non-transgenic male mice starting
at 16 weeks of age (#, p < 0.05). However, the weight difference between AR F23A 108Q and AR 112Q male mice was absent by 20 weeks of age due to weight
loss of the AR 112Qmalemice. This difference in the weights of AR 112Qmale mice in the full cohort (Figure 2C) comparedwith the pilot study shown here is likely
due to difference in the origins of the mice (see Experimental Procedures). (#, AR F23A 108Q significantly different than both ntg and AR 112Q; *, AR F23A 108Q
significantly different than AR 112Q; **, AR F23A 108Q significantly different than ntg; ***, both AR 112Q and AR F23A 108Q significantly different than ntg).
See also Figures S1 and S2.(Brooks and Dunnett, 2009), the decreased size of AR F23A
108Q mice might explain their enhanced rotarod performance
compared with AR112Q mice. However, in a pilot study, AR
F23A 108Q males exhibited the same improved rotarod perfor-2314 Cell Reports 13, 2312–2323, December 15, 2015 ª2015 The Aumance compared with AR 112Q males (Figure 2E), despite
displaying comparable weights from 20weeks of age (Figure 2F);
different weights in the two cohorts are found only in the AR112Q
male mice (see Experimental Procedures). These results furtherthors
Figure 3. Preventing the N/C Interaction of
the polyQ-Expanded AR Delayed Additional
Measures of Motor Deficits in Male Mice
(A) AR F23A mutation delayed balance beam def-
icits from 12 weeks to 16 weeks of age in male AR
F23A 108Q mice (*p < 0.05).
(B) No difference in balance beam performance
was seen between females of the three cohorts
tested.
(C) At 6 months of age, AR 112Q males displayed
reduced vertical activity (*p < 0.05). No difference
was seen between AR F23A 108Q males and non-
transgenic or AR 112Qmice at this age, suggesting
an intermediate phenotype and a delay of rearing
deficits.
(D) AR F23A 108A mice displayed reduced clasp-
ing compared with AR112Q mice (*p < 0.05) at
7 months of age.
Error bars in all graphs represent SD.support the conclusion that preventing the N/C interaction
was responsible for the delayed rotarod deficits in AR F23A
108Q mice. Moreover, no difference in rotarod performance
was seen in the female cohort at all ages tested (Figure 2B);
mouse weights in the female cohorts were largely comparable
(Figure 2D). AR F23A 22Qmales with a normal polyQ-tract length
were initially slightly better than non-transgenic males but were
no different at later time points (p < 0.05) (Figure S2A).
We also evaluated motor function using a beam-crossing
assay. Both non-transgenic males and AR F23A 108Q males
crossed the 12 mm beam substantially faster than did AR
112Q males at 12 weeks of age (Figure 3A) (p < 0.05). However,
by 16 weeks of age, AR F23A 108Q males were also slower at
this beam-crossing test (Figure 3A); this deficit represents the
earliest sign of motor dysfunction observed in these mice. No
difference in the time to cross the beam was seen in the female
cohort (Figure 3B), indicating that this deficit in the AR 112Q
males, and eventually in the AR F23A 108Q males, is hormone
dependent.
We previously observed reduced rearing behavior in AR 112Q-
expressing mice at 6 months of age (Chevalier-Larsen et al.,
2004). Indeed, at 6 months of age, male AR 112Q mice showed
reduced vertical activity compared with male non-transgenic
mice (p < 0.05) (Figure 3C). However, AR F23A 108Q male
mice exhibited an intermediate phenotype, without statistically
significant differences from either AR 112Q or non-transgenic
male mice, indicating a delay in the development of rearing def-
icits. In addition, male AR 112Q, but not AR F23A 108Q-express-
ing mice, developed a clasping phenotype by 7 months of age
(Figure 3D).
Blocking the N/C Interaction of the AR Reduced the
Decline in Grip Strength Despite Decreased Muscle
Weight
AR 112Q males develop a progressive decrease in grip
strength (Chevalier-Larsen et al., 2004); therefore, we next
examined the effect of the F23A mutation on grip strength.Cell RepAt 8 weeks of age, male AR 112Q mice demonstrated grip
strength equivalent to that of male non-transgenic mice (Fig-
ure 4A). However, by 6 months of age, male AR 112Q mice ex-
hibited a substantial decline in grip strength (Figures 4A and
4B). AR F23A 108Q male mice exhibited modestly decreased
grip strength at an early age compared with both AR 112Q
and non-transgenic male mice (Figure 4A). However, the grip
strength of AR F23A 108Q male mice did not decline with
age to the same extent as that of AR112Q male mice (Figures
4B and S3B). The grip strength of female AR F23A 108Q mice
was no different from that of female non-transgenic and female
AR 112Q mice at 10 weeks of age; however, the female AR
F23A 108Q mice failed to increase grip strength over time (Fig-
ures 4D and 4E), suggesting a hormone-independent feature
of the F23A mutation. Male AR F23A 22Q mice also showed
modestly reduced grip strength at both 8 and 24 weeks of
age (Figure 4G); however, this decrease was not progressive
in nature.
In order to understand the effects of the F23A mutation on
grip strength and given the impact of muscle size on grip
strength, we next evaluated the weight of the quadriceps mus-
cle from male and female mice. Male, but not female, AR112Q
mice showed a decrease in the weight of the quadriceps mus-
cle with age (Figures 4C and 4F), consistent with the progres-
sive nature of motor decline in these male mice. In contrast,
both male and female AR F23A 108Q mice exhibited a progres-
sive decline in muscle weight (Figures 4C and 4F), even though
the decline in grip strength was partially ameliorated in male
mice by the F23A mutation. Male F23A 22Q mice showed no
reduction in the relative weight of the quadriceps muscle (Fig-
ure 4H), suggesting that the effect of the F23A mutation on
grip strength in these mice might be due to the overall
decreased size of the mice (Figure S2B). Together, these re-
sults indicate that the F23A mutation partially ameliorated the
progressive decline in grip strength of male AR polyQ-
expanded mice, even though it decreased muscle weight in a
hormone-independent manner.orts 13, 2312–2323, December 15, 2015 ª2015 The Authors 2315
Figure 4. AR F23A Reduced the Progressive Decline in Grip Strength
(A and B) Grip strength was reduced in AR F23A 108Q male mice compared with AR 112Q and non-transgenic males at 8 weeks of age (*p < 0.05). While
non-transgenic mice showed a significant increase in grip strength from 8 to 24 weeks, AR 112Q and AR F23A 108Q mice showed a decline in grip strength (A)
(*p < 0.05). However, the F23A mutation reduced the extent of the age-dependent decline in grip strength caused by polyQ-expanded AR (B).
(C–E) AR F23Q 108Q mice showed decreased quadriceps weight (presented as a ratio of muscle weight to body weight) compared with non-transgenic and AR
112Qmale mice at 8 and 24 weeks of age (*p < 0.05). Quadriceps muscle weight in AR 112Qmale mice was significantly less than that of non-transgenic mice at
24weeks (*p < 0.05). Female AR F23A 108Qmice showed decreased grip strength comparedwith AR 112Q and non-transgenicmice at 24weeks of age (D), likely
attributed to a failure to significantly increase grip strength with age (E).
(F) No difference was seen in the quadriceps weight in the female mice at 10 weeks of age, but at 24 weeks, AR F23A 108Q mice had significantly smaller
quadriceps weights than did non-transgenic mice (*p < 0.05).
(G) AR F23A 22Q males showed reduced grip strength compared with non-transgenic mice at both 8 and 24 weeks of age.
(H) No difference in the weight of quadriceps muscles of non-transgenic and AR F23A 22Q male mice was observed.
Error bars in all graphs represent SD. See also Figure S3.We next carried out histologic evaluation of the quadriceps
muscle at 6 months of age in order to determine the basis for
the age-dependent decrease in weight of this muscle in the
transgenic mice. This analysis did not reveal any lesions consis-
tent with neurogenic atrophy. Additionally, thesemuscles did not
contain any significant necrosis, degeneration, fibrosis, mineral-
ization, or inflammation. There was no significant myofiber type
grouping in the NADH-TR stained sections. However, type II
muscle fiber area in both AR 112Q and AR F23A 108Q male
mice declined with age and at 6 months of age (Figure 5A) was
significantly smaller than muscle fiber area in non-transgenic
quadriceps. At this age, AR F23A trended toward reducing the
age-dependent decline in muscle fiber size observed in AR
112Q quadriceps, although the difference was not statistically
significant.
We next asked whether the decrease in muscle size in the
AR F23A 108Q line could be a direct effect of AR F23A on
the muscle. Transgene mRNA expression in quadriceps mus-
cles of AR F23A 108Q mice was significantly higher than that2316 Cell Reports 13, 2312–2323, December 15, 2015 ª2015 The Auof both AR 112Q mice (Figure 5B) and AR F23A 22Q mice
(Figure 5C), a finding not completely unexpected, given the
demonstration of low levels of PrP promoter-driven transgene
expression in multiple tissues, including muscle (Borchelt
et al., 1996). Muscle size is influenced by the anabolic function
of androgens acting through the AR (MacLean et al., 2008).
Additionally, preventing the N/C interaction decreases the
transcriptional activity of the AR (He et al., 2000). Therefore,
we wondered whether AR F23A 108Q might act in a domi-
nant-negative manner to repress the activity of endogenous
AR in muscle, thereby influencing muscle size. To determine
whether the higher AR F23A expression in muscle had an ef-
fect on endogenous AR function, we examined the expression
of AR responsive genes in quadriceps muscle. A trend toward
a decrease in expression of Amd1 and Odc1, two AR respon-
sive genes (Chua et al., 2015; MacLean et al., 2008), was
observed in the quadriceps muscles of AR F23A 108Q male
mice (Figures 5D and 5E), although these differences were
not statistically significant.thors
Figure 5. Muscle Analysis of AR F23A and AR 112Q Mice
(A) Type II muscle fiber area was significantly lower in both AR 112Q mice and AR F23A 108Q mice, compared with non-transgenic mice, at 24 weeks of age
(*p < 0.05).
(B) Transgene expression, determined by quantitative RT-PCR (qRT-PCR), was lower in both the spinal cord and quadriceps muscle of AR 112Qmice compared
with AR F23A 108Q mice.
(C) Despite very high transgene expression in the spinal cord of AR F23A 22Q mice, transgene expression in the quadriceps muscle of AR F23A 22Q mice was
significantly lower than in the quadriceps muscle of AR F23A 108Q mice (*p < 0.05).
(D and E) No significant difference in Amd1 (D) and Odc1 (E) expression, two AR responsive genes, was observed in the quadriceps muscle of male mice at
6 months of age.
Error bars in all graphs represent SD.Blocking the AR N/C Interaction Restores the NFH
Phosphorylation State and Decreases Aggregation in
Motor Neurons of the Spinal Cord
Given that the AR F23A mutation delayed motor deficits in male
mice, we next sought to determine whether the mutation would
delay pathological correlates of disease. AR 112Q male mice
exhibit changes in neurofilament heavy chain (NFH) phosphory-
lation at ages associated with motor deficits (Chevalier-Larsen
et al., 2004). We evaluated the intensity of SMI32 immunofluo-
rescence in spinal cord ventral horn motor neurons at 4 months
of age, shortly after the onset of motor phenotypes in AR 112Q
mice. While a significant reduction in the intensity of SMI32
staining was observed in spinal motor neurons of AR 112Q
mice (Figures 6A and 6B), this decline was prevented by the
F23A mutation.
We previously found that the AR F23Amutation decreased ag-
gregation of polyQ-expanded AR in a PC12 cell model of SBMA
(Orr et al., 2010). Therefore, we investigated whether the F23A
mutation decreased AR aggregation in the spinal cord of AR
F23A 108A-expressing mice. Analysis of AR inclusions in the
neurons of the spinal cord ventral horn at 6 months of age re-
vealed a reduced number of neurons containing AR inclusions
in male AR F23A 108Q mice (Figure 6B). Given this reduction,
we evaluated AR aggregation using a sensitive biochemical
assay, SDS-AGE; this assay resolves distinct AR aggregation
species (Heine et al., 2015). We observed a significant reduction
in fast-migrating AR aggregation species in AR F23A 108Q mice
(Figure 6C), consistent with the reduced appearance of nuclear
inclusions.Cell RepSerine 16 Phosphorylation Is Increased with F23A
Mutation
Our analysis of transgenic mice expressing polyQ-expanded AR
bearing the F23A mutation revealed that preventing the AR N/C
interaction delayed motor impairment and reduced indicators of
neuropathology. In order to determine the mechanistic basis for
this neuroprotection, we utilized a PC12 cell model that repro-
duces the hormone-dependent AR aggregation and toxicity
observed in SBMA patients (Montie et al., 2009, 2011; Orr
et al., 2010; Walcott and Merry, 2002). The AR is phosphorylated
at multiple sites and most of the phosphorylation sites reside in
the N-terminal domain of the protein (reviewed in Gioeli and
Paschal, 2012). We investigated whether changes in AR phos-
phorylation might play a role in the neuroprotection afforded by
blocking the N/C interaction. Utilizing this PC12 cell model that
expresses polyQ-expanded AR with or without the FxxLF muta-
tion (Orr et al., 2010), we found that phosphorylation of serine 16
was substantially increased when the FxxLF motif was mutated
to either F23A or L26/27A (Figure 7A). Moreover, the effect of the
F23A mutation on Ser-16 phosphorylation was recapitulated
in vivo, as observed in transgenic mice (Figure 7B).
Protective Effect of the F23A Mutation Is Dependent on
Serine 16
Phosphorylation of several polyQ-expanded proteins has a sig-
nificant effect on toxicity and aggregation of the mutant protein
(Chen et al., 2003; Emamian et al., 2003; Gu et al., 2009; Palaz-
zolo et al., 2007, 2009); therefore we investigated the role of
Ser-16 phosphorylation on the protective effects of the F23Aorts 13, 2312–2323, December 15, 2015 ª2015 The Authors 2317
mutation. To do this, we first made stable PC12 cell lines that
inducibly express AR F23A 110Q or AR F23A 10Q with Ser-16
mutated to a phosphonull alanine (S16A). We hypothesized
that, if increased phosphorylation plays a role in the neuropro-
tection afforded by the F23A mutation, the S16A mutation would
reduce these protective effects. Indeed, mutation of Ser-16 to
alanine (S16A) eliminated the protective effect of F23A on AR ag-
gregation (Figure 7C) and toxicity (Figure 7D). This effect was
polyQ length dependent, as AR 10Q, bearing S16A in the context
of F23A, did not form NI (Figure 7C) or cause toxicity (Figure 7D).
Given our finding that the S16A mutation eliminated the protec-
tion provided by the F23A mutation, we reasoned that mutations
that mimic Ser-16 phosphorylation would not alter this protec-
tion. Replacement of Ser-16 with either aspartate (Figures 7C
and 7D) to mimic Ser-16 phosphorylation, or two glutamate res-
idues (data not shown), tomore fully mimic the addition of charge
(Strickfaden et al., 2007), also eliminated F23A protection. It is
possible that these mutations do not accurately mimic the phos-
phorylated state of Ser-16. Manipulation of the kinase that regu-
lates Ser-16 phosphorylation, which is currently unknown, will
allow the more precise investigation of this post-translational
modification.
In order to further examine the role of Ser-16 in the protective
effects of F23A in cultured motor neurons, we used AAV to ex-
press AR F23A with or without the S16A mutation. Expression
of AR 112Q resulted in substantial DHT-dependent toxicity,
which was ameliorated by the F23A mutation (Figure 7E). The
S16A mutation eliminated F23A neuroprotection (Figure 7E),
further supporting the importance of Ser-16 in the neuroprotec-
tion provided by preventing the N/C interaction. Moreover,
consistent with our results using PC12 cells, the S16D mutation
similarly eliminated F23A neuroprotection (Figure 7E).
DISCUSSION
The N/C interaction of the AR is an interdomain interaction that
occurs upon hormone binding and is necessary for normal AR
function. Previous examination of the role of the N/C interaction
of the AR in SBMA has yielded conflicting results. A study per-
formed in a PC12 cell model of SBMA found that toxicity and ag-
gregation of the polyQ-expanded AR were prevented by either
the F23A or F26A/F27Amutations (Orr et al., 2010). Both of these
mutations disrupt the FxxLF motif of the AR and are directly
involved in mediating the interaction with the AF2 domain (He
et al., 2004). In contrast, a mutation outside the FxxLF motif,
G21E (Callewaert et al., 2003), was used to inhibit the N/C inter-
action and investigate the role of this interdomain interaction in a
Drosophila model of SBMA (Nedelsky et al., 2010). The G21E
mutation did not alter multiple degenerative phenotypes in this
SBMA model, bringing into question the importance of the N/C
interaction in disease in vivo. These contradictory results high-
lighted the importance of addressing the role of the N/C interac-
tion in a mammalian model of SBMA.
Here we demonstrate that genetically preventing the AR N/C
interaction delayed behavioral and biochemical deficits in a
mammalian model of SBMA. Motor impairments, such as ro-
tarod, beam walk, and rearing activity, were all substantially de-
layed in AR F23A 108Qmice, as was the progressive reduction in2318 Cell Reports 13, 2312–2323, December 15, 2015 ª2015 The Augrip strength. Additionally, the alteration of NFH phosphorylation
status, a biochemical correlate of disease, was prevented by the
F23A mutation. Together these findings provide evidence for an
important role of the N/C interaction in polyQ-expanded AR
toxicity in a mammalian model of disease. However, why these
results differ from those of Nedelsky et al. (2010) is unclear. It
is possible that the effects of the two mutations, F23A and
G21E, differ in preventing the N/C interaction in vivo. It may
also be that proteins that interact with the AR under the distinct
conformational states involving the N/C interaction differ be-
tween Drosophila, which does not contain an AR ortholog, and
mouse. Finally, it may be that the differences reflect diverged
roles or regulation of protein clearance in mouse and fly models,
which may represent early or late disease states, respectively.
Discordant effects of other proteins involved in neurodegenera-
tive diseases, namely mutant Huntingtin and a-synuclein, have
been observed in Drosophila and mouse models of Huntington’s
disease and Parkinson’s disease, respectively (Chen and Feany,
2005; Oueslati et al., 2013; Thompson et al., 2009). Despite these
differences, the decreased toxicity afforded by the F23A muta-
tion in mice, described here, suggests that the N/C interaction
represents a valid therapeutic target.
Given our finding that preventing the AR N/C interaction de-
layed disease in vivo, we sought to determine the mechanism
for this effect. We show here that Ser-16 is hyperphosphorylated
when the N/C interaction is genetically blocked; therefore, we
investigated the role of this phosphorylation in the protective
effect of AR F23A. We discovered that inhibition of Ser-16 phos-
phorylation by genetic mutation (S16A) eliminated F23A protec-
tion, as predicted if Ser-16 phosphorylation plays a critical role in
this mechanism. Although mutations designed to mimic Ser-16
phosphorylation also prevented F23A protection, it is possible
that these mutations (S16D, replacement of S16 with an EE
dipeptide) do not accurately reproduce the phosphorylation of
Ser-16. It is also possible that Ser-16 itself, and not its phosphor-
ylated state, is critical for F23A protection. Ser-16 phosphoryla-
tion does not respond to hormone binding (Yang et al., 2007).
However, phosphorylation of Ser-16 is actively maintained; inhi-
bition of PP2A, a phosphatase that regulates its phosphorylation,
results in increased Ser-16 phosphorylation (Yang et al., 2007).
Therefore, the increased phosphorylation seen in AR F23A could
be the result of a protein/protein interaction that blocks PP2A
binding at this site; such a protein interaction could be important
for the decreased toxicity and aggregation of AR F23A. A number
of proteins interact with the N-terminal domain of the AR (re-
viewed by Gottlieb et al., 2012), and any one of these could
potentially alter the amyloidogenic and toxic properties of
polyQ-expanded AR. Further exploration into the mechanism
underlying the Ser-16 requirement in F23A neuroprotection
could provide additional therapeutic targets for SBMA.
Mutation of the FxxLF motif is known to reduce AR transcrip-
tional activity (He et al., 2002). Whether the F23A mutation re-
duces a toxic transcriptional activity that contributes to disease
is untested by our studies here. Moreover, while we observed no
effect of AR F23A 108Q expression on the expression of two
neuronal AR target genes, neuritin (Fargo et al., 2008; Marron
et al., 2005) and nNOS (Singh et al., 2000) (data not shown),
whether there exists a broader effect of the F23A mutation onthors
Figure 6. Blocking the AR N/C Interaction Restores the NFH Phosphorylation State and Decreases Aggregation in Motor Neurons of the
Spinal Cord
(A) Spinal cords from 4-month-old mice were sectioned and immunostained for unphosphorylated-NFH (u-NFH, SMI32) and stained with Hoechst 33258 to
identify nuclei. AR 112Q mice showed a decrease in intensity of u-NFH staining in spinal motor neurons at 4 months of age compared with non-transgenic mice
(*p < 0.05). The F23A mutation prevented the decrease in u-NFH at this age (*p < 0.05) (right). Scale bar represents 25 mm.
(B) AR nuclear inclusions were examined in AR 112Q and AR F23A 108Q mice. Spinal cords from 6-month-old mice were sectioned and immunostained with
AR antibody (AR H280; green) and u-NFH antibody (SMI32; red) and stained with Hoechst. Nuclear inclusions were found in both AR 112Q and AR F23A 108Q
male mice, but the percentage of cells with nuclear inclusions was decreased by the F23A mutation (**p < 0.005) (right). Error bars represent SD. Scale bar
represents 10 mm.
(legend continued on next page)
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Figure 7. The Protective Effects of the F23A Mutation Are Dependent on Ser-16
(A and B) Ser-16 phosphorylation of expanded-polyQ AR is increased by genetically preventing the N/C interaction in vitro (A) and in vivo (B). (A) AR was
immunoprecipitated from PC12 cells, electrophoresed on SDS/PAGE, and probed with an antibody detecting phosphorylated Ser-16 (top) or an antibody de-
tecting total AR (bottom). (B) Immunoprecipitation frombrain nuclear extracts from one non-transgenic (ntg) (7 weeks old), two AR 112Q (7weeks old), and two AR
F23A 108Q (12weeks old) malemicewas carried out with anti-AR or control IgG antibodies as described in Experimental Procedures. Cell lysates fromPC12 cells
expressing AR F23A 110Q or AR S16A F23A 110Q were used as positive and negative controls, respectively, for phosphorylated Ser-16 AR. Levels of phos-
phorylated AR at Ser-16 (pSer16 AR, top panel) or total AR (bottom panel) were measured by western blotting using pSer or anti-AR (H280) antibodies. Asterisks
(*) indicate non-specific bands. (B, right) Band intensities for pSer16 AR or total AR from (B, left) were quantified using Image J and for each sample normalized to
AR F23A 110Q control signal. Error bars represent the range of two experiments. IB, immunoblotting; HMW, high molecular weight species.
(C) PC12 cells induced to express AR at equivalent levels were treated with DHT for 96 hr and then immunostained with AR antibody H280 and Hoechst to
visualize intranuclear inclusions. Mutating Ser-16 on AR F23A caused an increase in percentage of cells with intranuclear inclusions in a polyQ-length dependent
manner (*p < 0.05).
(D) PC12 cells induced to express AR at equivalent levels were treated with either ethanol or DHT for 12 days and then stained with trypan blue to determine the
percentage of non-viable cells. Mutating Ser-16 abolished the protective effect of the F23A mutation (*p < 0.05).
(E) Dissociated spinal cord cultures were infected with AAV expressing AR F23A 110Q or AR 112Q for 5 days and then treated with ethanol or DHT for 7 days.
Motor neurons were counted following immunostaining with unphosphorylated-NFH antibody SMI32. Mutation of Ser-16 abolished the protective effect of the
F23A mutation (*p < 0.05).
Error bars in all graphs represent SD.AR-regulated gene expression in the spinal cord is an ongoing
area of investigation.
Although the F23A mutation did delay many of the toxic
effects of polyQ-expanded AR, overexpressing AR F23A did
have adverse effects on muscle growth and grip strength,
regardless of sex. It is likely that the higher transgene expres-
sion in the quadriceps muscle of AR F23A 108Q mice, com-
bined with the decreased transcriptional activity of AR bearing
the F23A mutation (He et al., 2002), was responsible for the
decreased muscle size seen in AR F23A 108Q mice. Muscle
size is strongly influenced by AR activity (MacLean et al.,(C) Aggregation state of AR F23A 108Q and AR 112Q in vivo. Nuclear extracts from
resolved on an SDS-agarose gel, followed by immunodetection with anti-AR antib
Signal intensities of fast-migrating species were quantified using Image J. Error b
followed by western blot analysis of nuclear extracts from (A) reveals AR monom
2320 Cell Reports 13, 2312–2323, December 15, 2015 ª2015 The Au2008); therefore, a decrease in AR activity could explain the
smaller muscle size in both male and female mice. Consistent
with this idea, we observed a trend toward decreased expres-
sion of two AR-responsive genes in quadriceps muscle of aged
male mice, suggesting a possible dominant negative effect of
AR F23A in the muscles of these mice. This change, however,
was modest. Alternatively, it may be that target genes other
than Amd1 or Odc1 are impacted by the F23A mutation. For
example, expression of the AR F23A 108Q transgene could
result in the activation of protein degradative pathways; such
activation might protect motor neurons from proteotoxicityspinal cords of three 7 month-old AR 112Q or AR F23A 108Qmale mice were
ody (H280). Fast-migrating AR species are indicated on the left. (Graph, right)
ars represent SD of three experiments. *p < 0.05. (Right, bottom) SDS-PAGE
er as well as high molecular weight species (HMW).
thors
but induce atrophy in muscle fibers, which are exquisitely sen-
sitive to altered levels of protein degradation (Milan et al.,
2015). Importantly, despite the effects of the transgene expres-
sion in muscle, motor phenotypes in F23A 108Q mice were de-
layed, further supporting the protective effect of the F23A
mutation.
Therapeutic approaches in SBMA have focused on the global
reduction of AR function by reducing androgen levels (Banno
et al., 2009; Katsuno et al., 2010; Ferna´ndez-Rhodes et al.,
2011). While these clinical trials identified potentially beneficial
outcomes from reducing AR activation (Ferna´ndez-Rhodes
et al., 2011; Katsuno et al., 2010), the global reduction in AR func-
tion can have deleterious effects on the mental well-being of
patients (Ferna´ndez-Rhodes et al., 2011). Moreover, in recent
clinical trials (Rhodes et al., 2009; Yamamoto et al., 2013), the
observed correlation between muscle strength and testosterone
levels suggests that the anabolic effects of AR function in muscle
should be considered in the development of effective therapies
for SBMA.
Here we identified a conformational state of the AR that, when
prevented, substantially delays motor deficits in a mouse model
of disease. Advances in the field of prostate cancer have pro-
duced novel AR ligands that inhibit the N/C interaction, and
function as potent AR antagonists (e.g., flutamide, bicalutamide,
Enzalutamide). At least one N/C-inhibiting AR antagonist, fluta-
mide, provides neuroprotection in several mouse models of
SBMA (Renier et al., 2014). Other N/C interaction-inhibiting com-
pounds have been discovered that function as partial AR ago-
nists, activating AR transcriptional activity (Kazmin et al.,
2006). Using such compounds to treat SBMA could prevent
the adverse effects of global or even regional reduction in AR ac-
tivity. Whether such N/C-inhibiting agonists, already shown to
provide neuroprotection in vitro in SBMA models (Orr et al.,
2010), will be effective in vivo will be the topic of future studies.
Additionally, further exploration into the mechanism underlying
the role of the N/C interaction in disease could identify additional
therapeutic targets.
EXPERIMENTAL PROCEDURES
Transgene Construction and Mouse Generation
The AR cDNA containing the F23Amutation and a CAG repeat tract of either 22
or 110 was cloned into the Xho1 restriction site of the PrP plasmid as previ-
ously described (Chevalier-Larsen et al., 2004). The plasmid backbone was
removed by NotI digestion, and the AR-containing fragment was gel purified
and injected into fertilized oocytes (B6D2N2) by the Sidney Kimmel Cancer
Center Transgenic Facility at Thomas Jefferson University. All procedures
were performed following the guidelines of the Office of Laboratory Animal
Welfare and with the approval of the Thomas Jefferson University Institutional
Animal Care and Use Committee. Additional details on transgenic mouse gen-
eration and characterization can be found in Supplemental Experimental
Procedures.
Analysis of Motor Function
Motor function of male and female ARF23A 108Q and ARF23A 22Q mice was
compared with that of age-matched male or female AR 112Q mice and non-
transgenic mice; all assays were carried out by an investigator blinded to the
animal genotypes. The following cohorts were generated for behavior assess-
ment: male polyQ-expanded AR (ntg = 22, F23A = 22, SBMA = 20), female
polyQ-expanded AR (ntg = 20, F23A = 20, SBMA = 16), male AR F23A 22Q
(ntg = 18, F23A = 15). All lines were assessed using a continuously acceleratingCell Rep(4–40 rpm over 10 min) rotarod (UgoBasile). Rotarod training and analysis
began at 8 weeks of age and consisted of four trials per day for 3 consecutive
days; results (latency to fall) from the third day were kept for analysis. Mice
were tested once every 4 weeks using four trials withR15 min between trials.
Significance was determined using two-way repeated-measures ANOVA and
Tukey post hoc analysis (SigmaStat). Additional details onmotor function anal-
ysis can be found in Supplemental Experimental Procedures.
Dissociated Spinal Cord Cultures
Dissociated spinal cord cultures were initiated as described previously (Mon-
tie et al., 2009; Roy et al., 1998). Briefly, spinal cords removed from embryonic
day 13.5 non-transgenic mice were pooled on ice, dissociated with trypsin,
and then plated on poly-D-lysine coated coverslips in 24-wells plates. Cul-
tures were grown in glia-conditioned media containing minimal essential me-
dium, 3% charcoal-stripped horse serum, 35 mM NaHCO3, 0.5% dextrose,
1% N3, and 10 nM 2.5S nerve growth factor for 3 weeks prior to infection
with virus. Five days after infection, cultures were treated with either ethanol
or DHT for 7 days and then analyzed as previously described (Montie et al.,
2011).
Nuclear Extracts of Mouse Tissue
Dissectedmouse spinal cords or brains were homogenized in hypotonic buffer
(10 mM HEPES-NaOH [pH 7.9]), 1.5 mM MgCl2, 10 mM NaCl, 0.5 mM DTT
supplemented with EDTA-free protease inhibitor cocktail (Roche Diagnostics
GmbH), 100 mM NaF, 200 mM Na3VO4, 100 nM okadaic acid, and 0.1% phe-
nylmethylsulfonyl fluoride (diluted from a saturated stock solution prepared in
isopropanol) and centrifuged at 3,000 3 g for 10 min at 4C. Nuclear pellets
were resuspended in 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2% SDS (sup-
plemented with protease and phosphatase inhibitors as above), flash frozen
in liquid nitrogen, and stored at 80C.
Immunoprecipitation
Brain nuclear extracts (prepared as described above) were diluted to achieve a
final buffer composition of 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% SDS
(supplemented with protease and phosphatase inhibitors as above) and then
rotated on a rotary platform for 30 min at 4C. Samples were centrifuged at
15,000 3 g for 15 min, and the supernatant was subjected to immunoprecip-
itation as follows. Two milligrams of nuclear extracts (in 2 ml) were incubated
with 20 mg of anti-AR antibody (G122-434, BD Biosciences) or mouse control
IgG (Santa Cruz Biotechnology) (crosslinked to Dynabeads M-270 Epoxy
[Invitrogen] according to the manufacturer’s instructions) and incubated with
rotation overnight at 4C. Antibody-bound beads were washed four times
with 1 ml of the same buffer and then resuspended in 30 ml of 2 3 Laemmli
buffer, followed by SDS-PAGE and immunoblotting.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and three figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2015.11.019.
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